Massachusetts Financial Services Co. MA Decreases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Massachusetts Financial Services Co. MA reduced its position in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 10.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 116,245 shares of the medical equipment provider’s stock after selling 14,012 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Hologic were worth $8,067,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Deseret Mutual Benefit Administrators increased its position in shares of Hologic by 312.4% during the second quarter. Deseret Mutual Benefit Administrators now owns 367 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 278 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Hologic during the third quarter valued at about $29,000. NBC Securities Inc. acquired a new stake in shares of Hologic during the third quarter valued at about $33,000. Clear Street Markets LLC increased its position in shares of Hologic by 91.3% during the first quarter. Clear Street Markets LLC now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 231 shares during the last quarter. Finally, Salem Investment Counselors Inc. increased its position in shares of Hologic by 163.9% during the second quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 341 shares during the last quarter. 92.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on HOLX. Raymond James lifted their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Morgan Stanley dropped their price objective on shares of Hologic from $86.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, November 13th. UBS Group lifted their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. William Blair restated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Finally, Needham & Company LLC lifted their price objective on shares of Hologic from $83.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 2nd. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $86.89.

Get Our Latest Stock Report on Hologic

Hologic Stock Up 0.0 %

Shares of Hologic stock opened at $73.44 on Monday. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88. The company has a 50 day moving average of $72.13 and a 200 day moving average of $71.92. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $17.24 billion, a P/E ratio of 34.81, a P/E/G ratio of 2.48 and a beta of 1.02.

Hologic (NASDAQ:HOLXGet Free Report) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. As a group, research analysts forecast that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Essex D. Mitchell sold 7,500 shares of Hologic stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $71.85, for a total value of $538,875.00. Following the completion of the transaction, the insider now owns 12,827 shares in the company, valued at $921,619.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Karleen Marie Oberton sold 14,940 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the sale, the chief financial officer now owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Essex D. Mitchell sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $71.85, for a total transaction of $538,875.00. Following the sale, the insider now owns 12,827 shares of the company’s stock, valued at approximately $921,619.95. The disclosure for this sale can be found here. Insiders sold 32,440 shares of company stock worth $2,346,475 over the last 90 days. 1.75% of the stock is owned by insiders.

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Recommended Stories

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.